Expert Consensus on Risk Management of Polypharmacy in Elderly

Abstract

Abstract: China has the largest elderly population in the world. Polypharmacy in the elderly with multiple diseases is inevitable and very common. In recent years, more and more medical and pharmaceutical experts appeal to pay attention to the risk of polypharmacy in elderly, and put forward management to avoid damage caused by drug interaction in multi-drug combination therapy. To meet the needs of clinical practice and further to improve the level of drug safety in elderly, a group of clinical medicine and pharmaceutical experts in China have worked out the "Expert Consensus on the Risk Management of Polypharmacy in Elderly" for clinical reference to ensure the safety of drug use.

Key words: elderly, polypharmacy, risk management, expert consensus

CLC Number:

R969.3

Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology. Expert Consensus on Risk Management of Polypharmacy in Elderly[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 627-640.

References

[1] 殷立新,张立辉 . 特殊人群用药指导丛书:老年人用药指导[M]. 北京:人民卫生出版社,2012.
[2] 陶立群. 我国老年慢性病现状及发展趋势[J].老龄问题研究,2006(3):17-29.
[3] Ji L,Hu D,Pan C,et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J]. Am J Med,2013,126(10):925,e11-22.DOI:10.1016/j.amjmed.2013.02.035.
[4] Kaufmand W,Kelly J P,Rosenberg L,et al.Recent patterns of medication use in the ambulatory adult population of the United States:the slone survey[J]. JAMA,2002,287(3):337-344.
[5] Fialovd D,Topinkova E,Gambassi G,et al.Potentially inappropriate medication use among elderly home care patients in Europe[J]. JAMA,2005,293(11):1348-1358.DOI:10.1001/jama.293.11.1348.
[6] Kim H A,Shin J Y,Kim M H,et al.Prevalence and predictors of polypharmacy among Korean elderly[J].PLoS One,2014,9(6):e98043.DOI:10.1371/journal.pone.0098043.
[7] Lamd P,Mak C F,Chan S M,et al.Polypharmacy and inappropriate prescribing in elderly Hong Kong Chinese patients[J]. J Am Geriatr Soc,2010,58(1):203-205.DOI:10.1111/j.1532-5415. 2009. 02656.x.
[8] Johnell K,Klarin L.The relationship between number of drugs and potential drug-drug interactions in the elderly:a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register[J].Drug Saf,2007,30(10):911-918.
[9] 刘治军,韩红蕾. 药物相互作用基础与临床[J]. 3 版,北京:人民卫生出版社,2018.
[10] 张波,闫雪莲,王秋梅,等. 重视老年人多重用药问题[J]. 中华老年医学杂,2012,31(2):171-174.DOI:10.3760/cma.j.issn.0254-9026.2012.02.024.
[11] Kaku K .Efficacy of voglibose in type 2 diabetes[J]. Expert Opin Pharmacother,2014,15(8):1181-1190.DOI:10.1517/14656566.2014.918956.
[12] Balfour J A,Mctavish D.Acarbose.An update of its pharmacology and therapeutic use in diabetes mellitus[J]. Drugs,1993,46(6):1025-1054.
[13] Ahr H J,Boberg M,Krause H P,et al.Pharmacokinetics of acarbose.Part Ⅰ:absorption,concentration in plasma,metabolism and excretion after single administration of [14C]acarbose to rats,dogs and man[J].Arzneimittel for schung,1989,39(10):1254-1260.
[14] Miura T,Ueno K,Tanaka K,et al.Impairment of absorption of digoxin by acarbose[J].J Clin Pharmacol,1998,38(7):654-657.
[15] Morreale A P,Janerzky K.Probable interaction of warfarin and acarbose[J].Am J Health Syst Pharm,1997,54(13):1551-1552.
[16] Dash R P,Babu R J,Srinivas N R.Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose,voglibose and miglitol in the treatment of type 2 diabetes mellitus[J].Xenobiotica,2018,48(1):89-108. DOI:10.1080/00498254.2016.1275063.
[17] Scheen A J.Dipeptidylpeptidase-4 inhibitors (gliptins):focus on drug-drug interactions[J].Clin Pharmacokinet,2010,49(9):573-588. DOI:10.2165/11532980-000000000-00000.
[18] 陈莉明 .二肽基肽酶Ⅳ抑制剂类口服降糖药的药化性质和药理活性综合比较分析[J]. 中华糖尿病杂志,2016,8(8):508-510.
DOI:10.OI:10.3760/cma.j.issn.1674-5809.2016.08.014.
[19] Graefe-mody U,Retlich S,Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin[J].Clin Pharmacokinet,2012,51(7):411-427. DOI:10.2165/11630900-000000000-00000.
[20] Brown N J,Byiers S,Carr D,et al.Dipeptidyl peptidase- Ⅳ inhibitor use associated with increased risk of ACE inhibitor-associated angioedema[J].Hypertension,2009,54(3):516-523. DOI:10.1161/HYPERTENSIONAHA.109.134197.